Publicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (18)

2024

  1. The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers

    Current Oncology, Vol. 31, Núm. 9, pp. 5652-5661

2023

  1. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 796-802

  2. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

    The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106

  3. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

  4. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after

    Quality of Life Research, Vol. 32, Núm. 4, pp. 989-1003

2021

  1. Factors that Influence Treatment Delay for Patients with Breast Cancer

    Annals of Surgical Oncology, Vol. 28, Núm. 7, pp. 3714-3721

2019

  1. Cohort profile: Design and methods of the PREDIMED-Plus randomized trial

    International Journal of Epidemiology, Vol. 48, Núm. 2, pp. 387-388o

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2015

  1. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

    BMC Cancer, Vol. 15, Núm. 1

  2. FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

    Oncotarget, Vol. 6, Núm. 42, pp. 44254-44273

2013

  1. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

2012

  1. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers

    BMC Medical Genomics, Vol. 5

2010

  1. Current perspectives of treatment of ductal carcinoma in situ

    Cancer Treatment Reviews, Vol. 36, Núm. 7, pp. 507-517

  2. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

2009

  1. Screening for epidermal growth factor receptor mutations in lung cancer

    New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967

1995

  1. Anti-islet cell and anti-insulin antibody production by CD5+ and CD5- B lymphocytes in IDDM

    Diabetologia: Clinical and Experimental Diabetes and Metabolism, Vol. 38, Núm. 1, pp. 62-72

1991

  1. A phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer

    Cancer, Vol. 68, Núm. 1, pp. 40-43

1989

  1. Anticipatory nausea and vomiting: Prevalence and predictors in chemotherapy patients

    Oncology (Switzerland), Vol. 46, Núm. 1, pp. 26-30